This study was designed to correlate the clonogenic capacity of acute myeloid leukemia (AML) cells with P-glycoprotein (Pgp) expression level and P-gp-mediated efflux capacity. Fifty AML cell samples were tested for P-gp expression using MRK16 monoclonal antibody and flow cytometry. Among them, 12 samples were selected for sorting experiments according to the following two criteria: their clonogenic capacity in methylcellulose in the presence of 5637 conditioned medium, and the heterogeneity of P-gp distribution in leukemic cells. For each of these 12 samples, leukemic cells which displayed the highest P-gp expression level (P-gp ؉؉ ) and P-gp ؊ leukemic cells were sorted after MRK16 staining and seeded into methylcellulose for primary clonogenic assay. In each case, the number of CFU-L in the P-gp − fraction was significantly higher than that of the P-gp dull and Rh 123 bright populations, respectively. Altogether this study suggests that, for an individual AML cell population, the clonogenic fraction is preferentially recruited in AML cells which display low P-gp expression and high P-gp-mediated efflux capacity.
Introduction
Acute myeloid leukemia (AML) is a neoplastic disorder characterized by both the proliferation and the accumulation of leukemic blast cells of myeloid origin that cannot enter normal granulo-monocytic differentiation. 1 The AML cell population consists of hierarchical subpopulations including a minority of proliferating progenitors (AML-CFU). These AML-CFU may either self-renew or proceed to limited differentiation. The latter pathway provides the blast cells in terminal division, which represents the vast majority of the malignant cell population in AML patients (bulk leukemic cells). 2 Among the drugs widely used in the treatment of AML is the anthracycline daunorubicin (DNR), most often administered in combination with cytosine arabinoside. This regimen induces in most patients a complete remission, and therefore appears to be highly effective against terminal blast cells whereas the high incidence of relapse suggests that these drugs are poorly effective against AML progenitors. This clinical observation illustrates the inherent chemoresistance of immature myeloid leukemic cells. In fact, the CD34 glycoprotein, which is expressed on immature myeloid cells, has been generally correlated with lower remission induction rate and shorter overall survival. [3] [4] [5] [6] [7] [8] [9] [10] Among different mechanisms considered responsible for the chemoresistance of immature myeloid leukemic cells to DNR, the multidrug resistance phenotype (MDR) appears to play an important role. Indeed, in bulk leukemic cells taken from the blood or the marrow of patients with de novo or secondary AML, as well as in AML cell lines, CD34 expression has been correlated with both the mdr1 gene and P-glycoprotein (Pgp) overexpression. [11] [12] [13] [14] [15] Moreover, further studies have shown that CD34 + P-gp + AML cells present higher P-gp-mediated drug efflux capacity than CD34 − P-gp + AML cells, suggesting that P-gp function is enhanced in immature AML cells. [16] [17] [18] MDR1 expression in immature myeloid leukemic cells mirrors the CD34 + /MDR1 phenotype of normal hematopoietic stem and progenitor cells. 19 These observations support the hypothesis that, in myeloid cells, P-gp expression and/or function are inversely correlated with their maturation stage along the granulo-monocytic differentiation pathway. However, since bulk AML cells comprise both a minority of clonogenic cells and a majority of terminally differentiated cells, the detection of P-gp in circulating leukemic cells provides no valid information on the P-gp status of AML-CFU which appears to be the critical cellular compartment for AML chemotherapy. Indeed, since AML-CFU represents a less mature cell population compared to the terminally differentiated AML cells, it is conceivable that P-gp expression and function could be substantially different between these two populations.
In most AML cell samples, flow cytometric detection of Pgp in bulk leukemic cells reveals a high degree of variability in intensity staining and distribution. Similarly, a recent study showed that, in AML cell populations, blast cells may also display variable P-gp-mediated efflux capacity. 17 From the above findings, it is reasonable to speculate that leukemic progenitors should be recruited among AML cells which display high P-gp expression levels and/or P-gp-mediated efflux capacity.
Taking advantage of the heterogeneity of P-gp expression and function in bulk AML cells, this study was designed to correlate the clonogenicity of AML cells sorted on the basis of their P-gp expression level and efflux capacity. 
Materials and methods

Antibodies and chemicals
Clonogenic assay
Leukemic blast primary colony (CFU-L) assay was performed as previously described 20 with slight modifications. 21 Briefly, 1 × 10 5 cells were resuspended in IMDM supplemented with 30% FCS, 0.5 mM ␤-mercaptoethanol (Life Technologies, Grand Island, NY, USA), 0.9% methylcellulose (Fisher Scientific, Boston, MA, USA), 10% human bladder carcinoma cell line 5637 conditioned medium (5637 CM). A total of 10 5 cells was then plated in 35 mm Petri dishes in triplicate and incubated at 37°C in a humidified atmosphere of 5% CO 2 . After 7 days, colonies (more than 20 cells) and clusters (more than five cells) were scored under an inverted microscope. In each case, the leukemic myeloid nature of AML colony-forming unit was assessed by morphological study after Giemsa staining, cytochemistry (Sudan Black B and non-specific esterases) and immunophenotypic analysis from pooled colonies. 
Determination of surface membrane glycoproteins by flow cytometry
Fifty AML cell samples were tested for CD33, CD34 and MRK16 reactivity assessed by flow cytometry as described elsewhere. 18 Briefly, after thawing, cells were washed twice in phosphate-buffered saline (PBS) medium supplemented with 1% bovine serum albumin (BSA) and counted. 1 × 10 6 cells were incubated with the MoAb (1 g/ml for fluoresceinconjugated anti-CD33 and anti-CD34 MoAbs, and 2.5 g/ml for MRK16) for 30 min at 4°C then washed twice in PBS with 1% BSA at 4°C. For MRK16 only, cells were further incubated with diluted phycoerythrin-conjugated anti-mouse IgG1 antibody. Irrelevant isotype-matched MoAbs were used as negative controls. The samples were analyzed using an EPICS elite flow cytometer (Coulter, Hialeh, FL, USA). Gating of the leukemic cells on the flow cytometer was based on linear forward angle light scatter (FS) and right angle side scatter (SS). The samples were considered CD34 + or CD33 + when the percentage of stained leukemic cells in the gated fraction was higher than 20%. In the gated fraction, normal P-gp expressing cells contributed minimally to the measured level of P-gp expression. Indeed, the use of a mixture of anti-CD3, CD22 and anti-CD56 MoAbs coupled to phycoerythrin (PE) revealed that the total of T, B and NK cells never exceeded 5% of the gated cells (data not shown). Moreover, in the CD34
+ AML cell samples, we used a double staining with MRK16-PE and anti-CD34-FITC. In each case, double staining revealed that MRK16-stained cells were CD34
+ demonstrating that P-gp 
Rhodamine efflux analysis
The same samples were tested for their capacity to efflux Rhodamine 123 (Rh 123) as previously described. 18 Briefly, cells (range 5 × 10 5 to 10 × 10 5 cells/ml) were stained at 37°C in IMDM supplemented with 10% FCS in the presence of 150 ng/ml Rh 123 with or without 1 M PSC833, as P-gp inhibitor. After 10 min incubation at 37°C, an aliquot was removed and kept on ice until analysis (loading value). The remaining cells were washed twice with ice-cold media and resuspended in Rh 123-free medium at 37°C with or without 1 M PSC833. At various times (30 min, 1, 2, 3 and 4 h) an aliquot was removed, and after washing, kept on ice until analysis. Samples were analyzed on a Coulter Epics Elite flow cytometer (excitation wave length = 505 nM; emission wave length = 534 nM). As for P-gp detection, gating of the leukemic cells was based on linear forward angle light scatter (FS) and right angle side scatter (SS). The results were expressed as mean intensity fluorescence value either after loading or after 4 h efflux in Rh 123-free medium with or without PCS833. Results were also expressed as the ratio between residual fluorescence signal after 4 h incubation in Rh 123-and PSC833-free medium and mean fluorescence loading value without PSC833 (Table 2 ).
Cell sorting procedure according to P-gp expression Among the 50 AML samples, 12 were selected for sorting experiments according to the two following criteria: (1) their ability to generate clonogenic cells in methylcellulose in the presence of 5637 CM; and (2) the sample displayed P-gp distribution heterogeneity in leukemic cells as determined by flow cytometry after MRK16 staining (Figure 1 ). For each sample, 1 × 10 5 AML cells among those which displayed the highest P-gp expression (P-gp ++ ), as well as the same number of P-gp − AML cells, were sorted and seeded into semi-solid medium for clonogenic assays as described above. In preliminary experiments, we assessed that the clonogenic capacity of the cells was not affected by staining and sorting procedure (data not shown). Furthermore, sorting procedure was controlled by reanalysis of a fraction of the two sorted cell populations (data not shown).
Cell sorting procedure according to Rh 123 efflux capacity Among these 12 samples, six of them (samples 1-6) were selected because of their high Rh 123 efflux capacity (less than 60% fluorescence retention after 4 h incubation with Rh 123- and PSC833-free medium) ( Table 2 ). These samples displayed heterogeneity in Rh 123 effluxing capacity (Figure 2 ). For each sample, 1 × 10 5 AML cells among those which displayed the lowest residual fluorescence intensity after 4 h incubation (Rh 123 dull fraction) as well as an equivalent number of leukemic cells which displayed the highest residual fluorescence signal at 4 h (Rh 123 bright fraction), were sorted and seeded into semisolid medium for clonogenic assays as described above. In preliminary experiments, we assessed that the clonogenic capacity of the cells was not affected by Rh 123 loading and sorting procedure (data not shown). Furthermore, sorting procedure was controled by reanalysis of a fraction of the two sorted cell populations (data not shown).
Statistical analysis
Statistical analysis was performed using non-parametric test of paired values (Wilcoxon test). Differences with a P value equal or less than 0.05 were considered as significant.
Results
Patients' characteristics
Eleven patients were studied at diagnosis; only one (patient 9) received prior therapy and was studied in relapse. Half of the patients had secondary leukemia. AML phenotypes were Table 1) . Among the 12 AML cell samples, the percentage of P-gp expressing leukemic cells varied from 12 to 80% (Table 2 ). In each sample, P-gp distribution among the P-gp + fraction was heterogeneous as depicted in Figure 1 . Rh 123 efflux capacity was highly variable (Table 2) . Six samples (patients 7-12) displayed low (more than 70% Rh 123 fluorescence retention after 4 h) or undetectable Rh 123 efflux capacity. Some of these samples (Nos 8, 9, 10) still displayed a high number of P-gp expressing cells (22-50%), suggesting that these P-gp + AML cells displayed no functional P-gp. However, six samples (patients 1-6) displayed significant although variable Rh 123 efflux capacity. Indeed, in these samples Rh 123 fluorescence signal retention varied from 9 to 53% of the loading values after 4 h incubation in Rh 123-and PSC833- 
Differences between Pgp
++ and Pgp − CFU-L numbers were statistically significant with a P value Ͻ0.01.
free medium with no apparent correlation between Rh 123 efflux capacity and the percentage of P-gp expressing AML cells. In each case Rh 123 efflux was inhibited by PSC833 (Table 2 and Figure 2 ).
Clonogenic capacity of AML cells according to P-gp expression
In each of the 12 selected samples, AML cells were sorted between P-gp − (gate a) and P-gp ++ (gate b) (Figure 1 ), then the clonogenic capacities of the two fractions were compared using CFU-L assay (Table 3) . In each case the number of CFU-L in the P-gp − fraction was higher than that of the P-gp ++ fraction; the median number of CFU-L for 10 5 seeded cells being 147 (range 3-1855) and 495 (range 60-4100) for P-gp ++ and P-gp − populations, respectively (P Ͻ 0.01).
Clonogenic capacity of AML cells according to Rh 123 efflux capacity
The clonogenic capacities of sorted Rh 123 dull and Rh 123 bright AML cell fractions of samples 1-6 were compared using CFU-L assay. In each case the number of CFU-L in the Rh 123 dull fraction was higher than that of the Rh 123 bright fraction; the median number of CFU-L for 10 5 seeded cells being 1025 (range 250-2240) and 296 (range 11-838) for Rh 123 dull and Rh 123 bright , respectively (P = 0.05) ( Table 4) . 
Discussion
This study was designed to correlate P-gp status of fresh AML cells with their clonogenic capacity. In the 12 samples studied, we found that AML cells with high P-gp expression level displayed lower clonogenic capacity than AML cells with no detectable P-gp. Since it is generally admitted that the clonogenic capacity of AML cells is inversely correlated with the leukemic cell maturation stage, this result suggests that mdr-1 gene expression increases with expansion/differentiation of the AML clone. Such a hypothesis conflicts with a previous study performed with normal bone marrow cells which demonstrated that mdr-1 gene expression is higher in the most primitive hematopoietic cell compartment compared to the more mature stage of normal myelopoiesis. 19 However, as far as leukemic myelopoiesis is concerned, it remained uncertain if mdr-1 gene expression level was modulated along the leukemic cell differentiation pathway. Indeed, previous studies showed the exposure to drugs which are known to promote myeloid cell differentiation actually increased mdr-1 gene expression in unselected, drug-selected and mdr-1 transfected human leukemic cells. 22, 23 Moreover, using a panel of seven unselected P-gp expressing myeloid leukemic cell lines, we found that P-gp expression level was much higher (up to 13-fold) in CD34 − CD38 + CD33 + AML cells than in less mature CD34 + CD38 − CD33 − AML cells. 18 Altogether these observations suggest that in contrast to normal hemopoietic stem and progenitors cells, mdr-1 gene expression is up-regulated when leukemic cells engage in differentiation. If true, this could mean that the detection of P-gp in the bulk AML cells as routinely performed in a clinical setting may not necessarily reflect the P-gp status of the most primitive leukemic cell compartment.
From these 12 samples, we selected six samples in which AML cells exhibited high Rh 123 efflux capacity (samples 1-6). In the latter, Rh 123 efflux was blocked by PSC833, a potent P-gp blocker. This observation suggests that Rh 123 efflux was likely due to P-gp even if it has been reported that other drug transport proteins such as the multidrug-related protein could be occasionally involved in Rh 123 transport. 24 However, it should be noticed that in three samples (2, 3 and 6) , there is an apparent contradiction between the low percentage of the P-gp expressing cells and high Rh 123 efflux capacity. In these samples it could be possible that the socalled P-gp − cells displayed very low levels of P-gp expression not detected because of suboptimal conditions of flow cytometry evaluation. In fact, we found that these cells expressed mdr-1 gene as detected by RT-PCR analysis (data not shown). For each of the six samples we found that the AML cell fraction with high Rh 123 efflux capacity (Rh 123 dull ) displayed higher CFU-L values than the AML cell fraction with low or no dye effluxing capacity (Rh 123 bright ). This observation suggests that CFU-L fraction displayed higher P-gp efflux capacity compared to more mature leukemic progenitors. This interpretation supports the idea that P-gp efflux capacity is inversely correlated with the maturation stage of AML cells. [16] [17] [18] Altogether these results suggest that for a given AML population the leukemic clonogenic fraction which can be considered as the critical cellular target of AML chemotherapy, was preferentially recruited among the AML cells which displayed both low P-gp expression and high P-gp efflux capacity. It is interesting to note that this apparent contradiction between low P-gp expression and high P-gp extruding efficacy has been also described in AML cell lines with an immature CD34 + CD38 − phenotype such as KG1a and KG1 cells, suggesting that P-gp function is boosted in immature AML cells, compared to more mature leukemic cells. 18 The mechanism by which P-gp function is up-regulated in these cells is still unknown. However, it has been reported that Pgp function may be influenced by a number of parameters including protein kinase C (PKC) activity 25 or phospholipid membrane composition. 26 Therefore, one can speculate that modifications of the membrane lipid composition and distribution as previously reported in CD34
+ AML cells 27 and/or PKC stimulation by oncogene variants 28 or by cytokines such as IL-3, 29 may contribute in enhancing P-gp function in immature AML cells.
Whatever the mechanism which accounts for high P-gp efflux capacity, these findings support the use of P-gp blockers in combination with anthracyclines in AML. Moreover, since it appeared that the expression and/or the function of P-gp may be different between bulk AML cells and CFU-L, our study provides some evidence that P-gp blockers may potentially offer a clinical benefit in AML therapy whatever the P-gp status of circulating blast cells.
